NCT05020236: A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments

Sponsor: Pfizer. Phase: PHASE3. Conditions: Multiple Myeloma